Tacrolimus for Animals

Tacrolimus

Tacrolimus is a calcineurin inhibitor used mainly in local veterinary immunomodulatory treatment. Dermatologic preparations target selected focal immune-mediated skin lesions and perianal fistulas. Appropriately formulated ophthalmic preparations have a separate role in immune-mediated ocular disease, particularly canine keratoconjunctivitis sicca. These formulations provide local exposure at different treatment sites.

Group

Topical calcineurin inhibitor

Mechanism of Action

Tacrolimus binds the intracellular immunophilin FKBP12, and the resulting complex inhibits calcineurin. Reduced activation of NFAT transcription factors decreases interleukin-2 and other cytokine signals required for T-cell activation. Local suppression of immune-mediated inflammation supports cutaneous and ocular effects. In keratoconjunctivitis sicca, reduced lacrimal inflammation and additional local effects can improve tear production.

Dose Rates

Dogs

Use / stageDoseRouteScheduleInstructions
Localized immune-mediated skin diseaseReference onlyTOPICALApply 0.1% ointment to affected localized lesions; amount per application is not specified. Canine application has been twice daily.
Perianal fistulaReference onlyTOPICALApply 0.1% ointment twice daily; may be used with systemic prednisolone in an individualized plan.

Cats

Use / stageDoseRouteScheduleInstructions
Localized immune-mediated skin diseaseReference onlyTOPICALApply 0.1% ointment to affected localized lesions; amount per application is not specified. Canine application has been twice daily.

Indications

  • Local treatment of selected immune-mediated skin lesions, including focal canine cutaneous lupus or other steroid-responsive dermatoses.
  • Treatment of selected canine perianal fistulas.
  • Ophthalmic treatment of canine immune-mediated keratoconjunctivitis sicca, including selected cases inadequately responsive to cyclosporine.
  • Specialist local treatment of selected other immune-mediated ocular disease, including chronic superficial keratitis.

Contraindications

  • Infection susceptibility requires caution; systemic safety is unestablished.

Interactions

  • No topical interactions are identified in the clinical guidance.

Adverse effects

  • Transient local burning or itch; systemic administration can cause severe GI injury.

Preparations

PreparationFormStrengthRoute
Tacrolimus ointment 0.1%Other1 mg / gTOPICAL
Tacrolimus ointment 0.03%Other0.3 mg / gTOPICAL
Compounded sterile tacrolimus ophthalmic solution 0.01%
For ocular use only; validated sterile compounding and formulation required. Not interchangeable with skin ointment.
Other0.1 mg / mLTOPICAL
Compounded sterile tacrolimus ophthalmic solution 0.03%
For ocular use only; not prepared from Protopic skin ointment.
Other0.3 mg / mLTOPICAL

Monitoring and Administration

Limit application to affected skin and prevent handler skin contact. Use the original formulation; do not extrapolate skin ointments to sterile ophthalmic use.

Compounded sterile tacrolimus 0.01-0.03% ophthalmic solutions/ointments have been described for keratoconjunctivitis sicca, including cyclosporine-resistant cases. Commercial Protopic skin ointment contains ocular-irritant excipients and must not be used in, or compounded into preparations for, the eye. Exact drop amount/frequency is not specified in the tacrolimus subsection.

Skin treatment is usually twice daily until controlled, then reduced to the minimum effective frequency. Additional localized indications include discoid lupus, pemphigus, pinnal vascular lesions and alopecia areata. Wear gloves or use an applicator; long-term cutaneous safety is incompletely characterized.

Scroll to Top